Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Results available

The BIomarker Guided (BIG) Study for Depression

NCT04181736
Conditions
Major Depressive Disorder
Interventions
Guanfacine Tablets
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Orthopedic Devices Associated With Misadventures
Interventions
Tenex Procedure, Open Debridement Surgical Intervention Treatment Plan
Procedure
Lead sponsor
Sean Mc Millan
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Burlington, New Jersey • Cherry Hill, New Jersey • Moorestown, New Jersey + 4 more
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
ADHD
Interventions
SPD503 (Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Phoenix, Arizona • El Centro, California • Rolling Hills Estates, California + 29 more
Conditions
Adhesive Capsulitis
Interventions
Tenex, Local anesthetic
Device · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Greater Trochanteric Pain Syndrome
Interventions
TENEX
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Does Guanfacine Attenuate Stress-Induced Drinking?

NCT02164422
Conditions
Alcohol Drinking
Interventions
Guanfacine 3mg/day, Guanfacine 1.5mg/day, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Attention Deficit Disorder With Hyperactivity, Autistic Disorder, Pervasive Development Disorders
Interventions
methylphenidate, guanfacine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
5 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Conditions
ADHD, Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Drug
Lead sponsor
Daniel Coury
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Portland, Maine + 7 more
Completed Phase 4 Interventional Results available

Guanfacine in Children With Tic Disorders

NCT01547000
Conditions
Tourette Disorder, Tourette Syndrome
Interventions
placebo, extended-release guanfacine (Intuniv)
Drug
Lead sponsor
Yale University
Other
Eligibility
6 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
New Haven, Connecticut • Tampa, Florida • New York, New York
Conditions
Chronic Pain
Interventions
Morphine, Guanfacine 1mg, Guanfacine 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lateral Epicondylitis (Tennis Elbow)
Interventions
Leukocyte rich platelet rich plasma, Percutaneous Tenotomy
Biological · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

NCT00935493
Conditions
Cognitive Aging
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
75 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Guanfacine for PONV and Pain After Sinus Surgery

NCT02882854
Conditions
Postoperative Nausea and Vomiting, Pain, Postoperative
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

NCT02259517
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine, Lisdexamfetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Cannabis Dependence
Interventions
Guanfacine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
SPD503, VYVANSE, SPD503 and VYVANSE
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Completed Phase 2 Interventional Results available

A Trial of Guanfacine-er for Cannabis Use Disorder

NCT05273567
Conditions
Cannabis Use
Interventions
guanfacine-ER, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Mindfulness, Guanfacine, Opioid Use Disorder
Interventions
Guanfacine pharmacotherapy, Mindfulness Oriented Recovery Enhancement (MORE)
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

NCT00672984
Conditions
Healthy Volunteers
Interventions
immediate release guanfacine hydrochloride, moxifloxacin, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment
Interventions
Guanfacine/Tenex
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
3
States / cities
New York, New York • The Bronx, New York • W. Brentwood, New York
Conditions
Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Interventions
Guanfacine Hydrochloride Immediate Release, Placebo
Drug
Lead sponsor
Rachel G. Greenberg, MD, MB, MHS
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah